Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Y Urasaki

Showing results (21-30 of 30) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 30 results.
Cancer Research|March 31, 2001
Characterization of a novel topoisomerase I mutation from a camptothecin-resistant human prostate cancer cell lineY Urasaki, G S Laco, P Pourquier, et al.
Leukemia Research|July 29, 1998
Idarubicin and idarubicinol are less affected by topoisomerase II-related multidrug resistance than is daunorubicinT Fukushima, H Inoue, H Takemura, et al.
Oncology Research|January 1, 1996
Superior cytotoxic potency of mitoxantrone in interaction with DNA: comparison with that of daunorubicinT Fukushima, Y Kawai, T Nakayama, et al.
Oncogene|August 16, 2006
Crk-associated substrate lymphocyte type regulates transforming growth factor-beta signaling by inhibiting Smad6 and Smad7S Inamoto, S Iwata, T Inamoto, et al.
International Journal of Hematology|July 17, 1999
Successful treatment of cytomegalovirus retinitis in a patient with malignant lymphoma: a case report and review of the literatureY Kawai, R Kawai, T Nakayama, et al.
Japanese Journal of Cancer Research : Gann|May 30, 2001
Monitoring of intracellular 1-beta-D-arabinofuranosylcytosine 5'-triphosphate in 1-beta-D-arabinofuranosylcytosine therapy at low and conventional dosesT Yamauchi, Y Kawai, S Kishi, et al.
Journal of Infection and Chemotherapy : Official Journal of the Japan Society of Chemotherapy|January 26, 2002
Long-term follow-up of the clinical efficacy of chemotherapy for acute myeloid leukemia at a single instituteT Seo, T Fukushima, H Inoue, et al.
Japanese Journal of Cancer Research : Gann|September 27, 2001
Close correlation of 1-beta-D-arabinofuranosylcytosine 5'-triphosphate, an intracellular active metabolite, to the therapeutic efficacy of N(4)-behenoyl-1-beta-D-arabinofuranosylcytosine therapy for acute myelogenous leukemiaT Yamauchi, Y Kawai, N Goto, et al.
Nature Medicine|August 2, 2001
Antiproliferative activity of ecteinascidin 743 is dependent upon transcription-coupled nucleotide-excision repairY Takebayashi, P Pourquier, D B Zimonjic, et al.
International Journal of Hematology|December 10, 1998
Response-oriented individualized induction therapy with six drugs followed by four courses of intensive consolidation, 1 year maintenance and intensification therapy: the ALL90 study of the Japan Adult Leukemia Study GroupT Ueda, S Miyawaki, N Asou, et al.
Pageof 3

Showing results (21-30 of 30) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 30 results.
Cancer Research|March 31, 2001
Characterization of a novel topoisomerase I mutation from a camptothecin-resistant human prostate cancer cell lineY Urasaki, G S Laco, P Pourquier, et al.
Leukemia Research|July 29, 1998
Idarubicin and idarubicinol are less affected by topoisomerase II-related multidrug resistance than is daunorubicinT Fukushima, H Inoue, H Takemura, et al.
Oncology Research|January 1, 1996
Superior cytotoxic potency of mitoxantrone in interaction with DNA: comparison with that of daunorubicinT Fukushima, Y Kawai, T Nakayama, et al.
Oncogene|August 16, 2006
Crk-associated substrate lymphocyte type regulates transforming growth factor-beta signaling by inhibiting Smad6 and Smad7S Inamoto, S Iwata, T Inamoto, et al.
International Journal of Hematology|July 17, 1999
Successful treatment of cytomegalovirus retinitis in a patient with malignant lymphoma: a case report and review of the literatureY Kawai, R Kawai, T Nakayama, et al.
Japanese Journal of Cancer Research : Gann|May 30, 2001
Monitoring of intracellular 1-beta-D-arabinofuranosylcytosine 5'-triphosphate in 1-beta-D-arabinofuranosylcytosine therapy at low and conventional dosesT Yamauchi, Y Kawai, S Kishi, et al.
Journal of Infection and Chemotherapy : Official Journal of the Japan Society of Chemotherapy|January 26, 2002
Long-term follow-up of the clinical efficacy of chemotherapy for acute myeloid leukemia at a single instituteT Seo, T Fukushima, H Inoue, et al.
Japanese Journal of Cancer Research : Gann|September 27, 2001
Close correlation of 1-beta-D-arabinofuranosylcytosine 5'-triphosphate, an intracellular active metabolite, to the therapeutic efficacy of N(4)-behenoyl-1-beta-D-arabinofuranosylcytosine therapy for acute myelogenous leukemiaT Yamauchi, Y Kawai, N Goto, et al.
Nature Medicine|August 2, 2001
Antiproliferative activity of ecteinascidin 743 is dependent upon transcription-coupled nucleotide-excision repairY Takebayashi, P Pourquier, D B Zimonjic, et al.
International Journal of Hematology|December 10, 1998
Response-oriented individualized induction therapy with six drugs followed by four courses of intensive consolidation, 1 year maintenance and intensification therapy: the ALL90 study of the Japan Adult Leukemia Study GroupT Ueda, S Miyawaki, N Asou, et al.
Pageof 3